BRAF and carcinoma: However recent studies, which used β-catenin immunohistochemistry rather than mutation analysis as a measure of Wnt pathway activation found nuclear β-catenin reactivity in a large part of BRAF mutant advanced (but not early) human adenomas and in carcinomas (Fujita et al., 2011; Yachida et al., 2009).